



Universiteit  
Leiden  
The Netherlands

## **Diagnostic and prognostic markers of cutaneous lymphomas**

Schrader, A.M.R.

### **Citation**

Schrader, A. M. R. (2020, August 27). *Diagnostic and prognostic markers of cutaneous lymphomas*. Retrieved from <https://hdl.handle.net/1887/136020>

Version: Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/136020>

**Note:** To cite this publication please use the final published version (if applicable).

Cover Page



Universiteit Leiden



The handle <http://hdl.handle.net/1887/136020> holds various files of this Leiden University dissertation.

**Author:** Schrader, A.M.R.

**Title:** Diagnostic and prognostic markers of cutaneous lymphomas

**Issue date:** 2020-08-27

Appendices

## **CURRICULUM VITAE**



## LIST OF PUBLICATIONS

**Schrader AMR**, Groen de RAL, Willemze R, Jansen PM, Quint KD, Cleven AHG, Wezel van T, Eijk van R, Ruano D, Tensen CP, Hauben E, Woei-A-Jin FJSH, Busschots A, Vermeer MH, Vermaat JSP. *Persistent oncogenic pathways drive primary cutaneous diffuse large B-cell lymphoma, leg type and their relapses*. Manuscript submitted.

Groen de RAL, **Schrader AMR**, Pals ST, Kersten MJ, Vermaat JSP. *MYD88 in the front seat of B-cell lymphomas: From molecular mechanism to clinical implications*. Review. *Haematologica*. 2019; 104(12): 2337-2348.

Vermaat JSP, Somers FS, Wreede de LC, Kraan W, Groen de RAL, **Schrader AMR**, Kerver ED, Scheepstra CG, Beerenschot H, Deenik W, Wegman J, Broers R, Boer de JD, Nijland M, Wezel van T, Veelken H, Spaargaren M, Cleven AHG, Kersten MJ, Pals ST. *MYD88 mutations identify a molecular subgroup of diffuse large B-cell lymphoma with unfavourable prognosis*. *Haematologica*. 2019; 105(2): 424-434.

**Schrader AMR**, Jansen PM, Vermeer MH, Kleiverda JK, Vermaat JPS, Willemze R. *High incidence and clinical relevance of MYC rearrangements in primary cutaneous diffuse large B-cell lymphoma, leg type*. *Am J Surg Pathol*. 2018; 42(11): 1488-1494.

**Schrader AMR**, Jansen PM, Willemze R, Vermeer MH, Cleton-Jansen AM, Somers SF, Veelken H, Eijk van R, Kraam W, Kersten MJ, Brand van den M, Stevens WBC, Jong de D, Abdul Hamid M, Tanis BC, Posthuma EFM, Nijland M, Diepstra A, Pals ST, Cleven AHG, Vermaat JSP. *High prevalence of MYD88 and CD79B mutations in intravascular large B-cell lymphoma*. *Blood*. 2018; 131(18): 2086-2089.

**Schrader AMR**, Chung YY, Jansen PM, Szuhai K, Bastidas Torres AN, Tensen CP, Willemze R. *No TP63 rearrangements in a selected group of primary cutaneous CD30<sup>+</sup> lymphoproliferative disorders with aggressive clinical course*. *Blood*. 2016; 128(1): 141-143.

Teunissen-Çetinözman F, **Schrader AM**, Jansen PM, Vermeer MH, Willemze R. *TOX en PD1: nieuwe diagnostische markers in cutane T-cellymfomen*. Ned Tijdschr Derm Venereol. 2016; 11(26): 689-692.

**Schrader AMR**, Jansen PM, Willemze R. *TOX expression in cutaneous B-cell lymphomas*. Arch Dermatol Res. 2016; 308(6): 423-427.

**Schrader AMR**, Jansen PM, Willemze R. *TOX expression in cutaneous T-cell lymphomas: an adjunctive diagnostic marker that is not tumour-specific and not restricted to the CD4<sup>+</sup>CD8<sup>-</sup> phenotype*. Br J Dermatol. 2016; 175(2): 382-386.

**Schrader AMR**, Deckers IE, Zee van der HH, Boer J, Prens EP. *Hidradenitis suppurativa: a retrospective study of 846 Dutch patients to identify factors associated with disease severity*. J Am Acad Dermatol. 2014; 71(3): 460-467.

**Schrader AMR**, Rác E, Noordhoek Hegt V, Snoek van der EM, Praag van MCG. *Granulomateuze secundaire syfilis: een zeldzame presentatie van een polymorf ziektebeeld*. Ned Tijdschr Geneesk. 2012; 156: A5130.

## NAWOORD

“

*If you want a happy ending,  
it just depends on where you close the book.*

- Orson Welles, 1915-1985

”

Met dank aan alle mensen die hebben bijgedragen aan de totstandkoming van dit proefschrift.